LeMaitre Will Announce Third Quarter 2022 Earnings Results October 27, 2022
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2022 financial results on October 27, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its third quarter 2022 financial results on October 27, 2022, after market close. A conference call is scheduled for 5:00 PM ET that same day to discuss the results, business highlights, and outlook. LeMaitre specializes in devices for peripheral vascular disease, which affects over 200 million people globally. The company manufactures and markets disposable and implantable vascular devices tailored for vascular surgeons.
Details
News Market Reaction – LMAT
The recorded move for LMAT in the trading session of this news was +0.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Oct. 17, 2022 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2022 financial results on Thursday, October 27, 2022, after the market close. The company has scheduled a conference call for 5:00 PM ET the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.
Contact:
Sandra Millar
LeMaitre Vascular, Inc.
+1-781-425-1686
smillar@lemaitre.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.